Profile: RTI Surgical Inc (RTIX.O)
12 Dec 2017
RTI Surgical, Inc., incorporated on April 25, 2000, is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company's business primarily consists of over six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties. The Company processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing BIOCLEANSE, TUTOPLAST and CANCELLE SP sterilization processes, and manufactures metal and synthetic implants for distribution to hospitals and surgeons.
The Company processes tissue at approximately two facilities in Alachua, Florida, and over one facility in Neunkirchen, Germany. It manufactures metal and synthetic implants in Marquette, Michigan and Greenville, North Carolina. The Company distributes its implants and services in approximately 50 states and in over 45 countries across the world. It distributes human tissue, bovine and porcine animal tissue, metal and synthetic implants through various distribution channels.
The Company designs, manufactures and distributes surgical implants and instruments used in the treatment of conditions affecting the spine and musculoskeletal system caused by degenerative conditions deformities or traumatic injury of the spine. Its surgical implants include allograft and synthetic interbodies, bone graft substitutes, rods, pedicle screws and plates.
The Company's ortho fixation category of products includes instruments and implants for trauma and cardio thoracic markets. The Company's trauma implants include devices used to stabilize damaged or broken bones. Its cardio thoracic implants include cable and plating systems used to close median sternotomies.
The Company's principal sports medicine allografts are tendons for ligament reconstruction, fresh osteochondral grafts for cartilage repair, and its meniscal allografts for advanced meniscus injuries. Many of the Company's sports medicine tendon allografts utilize its pre-shaped technology, which reduces preparation time in the operating room and are easier to implant as compared to non-pre-shaped allografts. The Company also distributes Matrix HD human dermis implants for wound repair and soft tissue augmentation. The Company's sports medicine implants include BioCleanse Meniscus, BioCleanse full tendon portfolio and fresh-stored osteochondral (OC) allograft portfolio.
BGS and General Orthopedics
The Company's BGS and general orthopedics category of products include map3, nanOss, allograft paste, milled allograft and xenograft, and conventional allografts. Its map3 cellular allogeneic bone graft is a natural and safe alternative to autograft that supports the body's innate healing mechanisms, and provides the scaffold and signals to support the bone healing process. The nanOss bone graft substitute consists of nano-structured hydroxyapatite granules suspended in a porous gelatin-based foam matrix. The allograft paste implants consists of demineralized bone matrix (DBM), and in some cases a biologic gel carrier, in fracture treatment, bone and joint reconstruction and periodontal applications, such as ridge augmentation for dental implants. Its allograft paste implants are marketed under the brands, such as Osteofil, Puros DBM, Optefil, Opteform, Regenafil and Regenaform. The Company also distributes directly the BioSet DBM, BioReady DBM and BioAdapt DBM families of paste implants. The Company's DBM Boat implants are marketed under BIO DBM brand. The Company's bone graft substitutes business also includes certain types of blended and milled bone allografts and xenografts, such as its demineralized bone matrix, cortical cancellous chips and ground cancellous chips, which are used in total hip and knee replacements and for various traumatic injuries. The Company's conventional allograft business includes a range of allograft categories, including its intercalary grafts, such as its structural grafts, which are used for cancer treatment procedures and hip and knee reconstruction. The Company also produces various types of fashioned bone, such as strips and shafts used for various orthopedic procedures.
The Company provides various implants, including cancellous and cortical bone and human and bovine membranes. Its implants are meant primarily for dental procedures related to augmenting ridge restoration.
The Company processes and distributes implants for surgical specialties, which include abdominal wall repair, plastic and reconstructive surgery, ophthalmology and urology. The Company distributes xenograft and allograft implants through its direct distribution organization. Its implants include Fortiva porcine dermis, Tutopatch and Tutomesh bovine pericardium and Cortiva human dermis.
The Company competes with Musculoskeletal Transplant Foundation, AlloSource Inc., Acelity L.P. Inc., LifeNet Health, Inc., Medtronic, PLC, Integra LifeSciences Holdings Corp., Wright Medical Inc., Baxter, Inc., Cook Surgical, Alphatec, Globus Medical Group, Inc., NuVasive, Inc. and Orthofix International NV.
RTI Surgical Inc
11621 Research Cir
ALACHUA FL 32615-6825
Company Web Links
- BRIEF-RTI Surgical receives warning letter from FDA
- BRIEF-RTI Surgical Q3 earnings per share $0.23
- BRIEF-RTI names Jonathon Singer as Chief Financial and Administrative Officer
- BRIEF-RTI Surgical Inc enters into a third amended and restated loan agreement
- BRIEF-RTI Surgical posts Q2 loss of $0.04 per share